• NorthBay Solutions Achieves AWS Managed Service Provider Designation

    AWS Premier Consulting Partner and AWS Migration Competency Partner joins an elite group of firms vetted and validated by AWS for top-tier expertise in all stages of the cloud journey. NorthBay AWS MSP Competency ANDOVER, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — NorthBay Solutions, a global Premier Consulting Partner in the Amazon Web Services (AWS) […]

  • NorthBay Solutions Achieves AWS Managed Service Provider Designation

    AWS Premier Consulting Partner and AWS Migration Competency Partner joins an elite group of firms vetted and validated by AWS for top-tier expertise in all stages of the cloud journey. NorthBay AWS MSP Competency ANDOVER, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — NorthBay Solutions, a global Premier Consulting Partner in the Amazon Web Services (AWS) […]

  • Miovision Acquires MicroTraffic

    Proprietary road safety analytics solution now part of the Miovision product portfolio KITCHENER, Ontario, Feb. 28, 2023 (GLOBE NEWSWIRE) — Miovision announced today that it has closed a deal to acquire Winnipeg-based MicroTraffic, a leading provider of road safety video analytics. According to a study by researchers at Toronto Metropolitan University, MicroTraffic’s proprietary approach can […]

  • Miovision Acquires MicroTraffic

    Proprietary road safety analytics solution now part of the Miovision product portfolio KITCHENER, Ontario, Feb. 28, 2023 (GLOBE NEWSWIRE) — Miovision announced today that it has closed a deal to acquire Winnipeg-based MicroTraffic, a leading provider of road safety video analytics. According to a study by researchers at Toronto Metropolitan University, MicroTraffic’s proprietary approach can […]

  • Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

    Ad Scientiam Logo PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) — On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage […]

  • Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

    Ad Scientiam Logo PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) — On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage […]

Categories
Monthly Archives